Novavax Inc NVAX shares are trading higher by 9.88% to $8.34 Thursday afternoon. The stock may be reacting to the company's presentations at the 2023 World Vaccine Congress this week.
At the WVC, Novavax presented data on its COVID-19 prototype vaccine as a booster and its CIC. Novavax also hosted an Insights and Tools to Counter Vaccine Hesitancy roundtable on April 4, and participated in a panel discussion on The Future of Safety for New Vaccines on April 5.
The stock is otherwise lower by 86% over the trailing year due to worse-than-expected sales results, a series of common stock offerings in December and amid broader market volatility.
According to data from Benzinga Pro, NVAX has a 52-week high of $76.77 and a 52-week low of $5.60.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
